Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 7 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

14%

1 trials in Phase 3/4

Results Transparency

0 of 1 completed trials have results

Key Signals

5 recruiting

Enrollment Performance

Analytics

Phase 2

2(28.6%)

Phase 1

2(28.6%)

Early Phase 1

2(28.6%)

Phase 3

1(14.3%)

7Total

Phase 2(2)

Phase 1(2)

Early Phase 1(2)

Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT07160400Phase 1Recruiting

A Study of IBI3032 in Chinese Healthy Participants and Participants With Overweight or Obesity

Role: lead

NCT07414394Phase 3Recruiting

Tigulixostat (IBI128) vs Febuxostat in Gout

Role: lead

NCT07327632Early Phase 1Recruiting

This is a Multi-Center Study of IBI3026 in Participants With Locally Advanced, Unresectable or Metastatic Solid Tumors

Role: lead

NCT07275840Phase 2Recruiting

A Study to Evaluate the Efficacy and Safety of IBI302inSubjects With nAMD

Role: lead

NCT07170319Phase 1Active Not Recruiting

A Study of IBI3032 in Chinese Participants With Overweight or Obesity

Role: lead

NCT07134127Early Phase 1Completed

A Study of IBI3032 in Chinese Healthy Subjects

Role: lead

NCT06908876Phase 2Recruiting

A Study to Evaluate the Efficacy and Safety of IBI302 inSubjects With Diabetic Macular Edema（DME）

Role: lead

All 7 trials loaded